Evaluation of Study Experiences of Neuroendocrine Tumor Patients (NCT05967481)
Investigating the Clinical Trial Journey and Engagement of Neuroendocrine Tumor Patients
🩺 Plain-English Summary (8th-Grade Level)
Taking part in clinical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups. This research will admit a wide range of data on the clinical study experience of neuroendocrine tumor patients to determine which factors prevail in limiting a patient's ability to join or finish a trial. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future patients with neuroendocrine tumor.
Who can join: Review the eligibility criteria below.
Location: Power Life Sciences — San Francisco, California
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Power Life Sciences — San Francisco, California
📞 Contact the Study Coordinator
Phone: (415) 900-4227
Email: bask@withpower.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Neuroendocrine Tumors
- Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients — Denver, Colorado
- Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors — Hamilton, Ontario
- A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors — Iowa City, Iowa
- Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients — Gilbert, Arizona
- Post-Authorization Long-Term Safety Study of LUTATHERA — Phoenix, Arizona
- Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors — Edmonton, Alberta
Explore by condition: All Neuroendocrine Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.